Thalidomide, beta blockers, tolbutamide, AZT and tamoxifen: the drugs featured in this book include some of the most anticipated, notorious and well-known prescription drugs in twentieth-century medicine. The edited volume brings together twelve case studies dating from the early nineteenth century to the present day, primarily covering France, Germany, the United Kingdom and the United States, but also including Brazil, India and the Netherlands. The editors take a broad definition of drug regulation and within this describe five ‘ways of regulating drugs’: professional, administrative, industrial, public and juridical. The argument for approaching regulation in this way is well made. Many of the case histories exemplify multiple ways of regulating, each of which has its own interactions, limitations and boundaries. This heuristic model thus brings some order to a complex subject, although some of the authors utilize the categorizations more explicitly than others. Crucially the classifications used facilitate both international and interdisciplinary comparisons and take into account the distinct social, political and economic worlds involved in regulation. The case histories explore not only the involvement of state authorities, professionals and pharmaceutical firms in regulation, but also the roles of patients, families, activists and consumer groups and other NGOs. The broadness of this approach provides new perspectives on therapeutic regulation and practice and clearly demonstrates that the history of drug regulation is not simply an account of the progress of better control.
As the remit of Palgrave's Science, Technology and Medicine in Modern History series requires, the volume ably demonstrates the value of close historical scrutiny for understanding, in this instance, current issues in pharmaceutical regulation. Case studies involving recent clinical trials, court cases and controversies sit comfortably alongside papers covering nineteenth- and early twentieth-century drug regulation. Volker Hess explores the introduction of a formal procedure for the scientific testing and approval of secret remedies in early nineteenth-century Prussia. He addresses how professionals can utilize their expertise to evaluate drugs without compromising scientific integrity or government authority, a question central to drug regulation today. Axel Hüntelmann examines the development and control of Salvarsan in early twentieth-century Germany and the resulting new form of regulatory science, which linked chemical and bacteriological screening. Jean-Paul Gaudillière's chapter explores the transformation from a professional way of regulating to an industrial one, by looking at the industrialization of the production of plant extracts in the interwar period at the French firm Dausse and the German firm Madaus. The late Harry Marks (to whose memory the book is dedicated) looks at professional and administrative regulation by re-evaluating the role of the US Food and Drug Administration (FDA). He argues that despite all the powers granted to it, the FDA was unable to effectively change or influence medical practice. Alberto Cambrosio, Peter Keating and Andrei Mogoutov approach professional regulation from a different perspective, conceptualizing it as a process of progressive ‘informational enrichment’ (p. 181). By focusing on the interaction between clinical research strategies and standardizing protocols, their study shows how cancer trials in the 1960s and 1970s consisted of implementing and altering complex regimens of treatment.
Donna Messner's case study illustrates how the administrative way of regulating responded to changes in the industrial way of regulating. She explains why the first antiretroviral drug AZT (azidothymidine) received marketing authorization even though the FDA's standard evaluation procedures had not been fulfilled. She then discusses how this in turn affected the reform of drug development and approval procedures, and shaped the growing AIDS activism movement. Jeremy Greene examines interactions between consumerism and administrative regulation in his study of letters from patients and doctors to the FDA, correspondence which followed revelations that the diabetic drug tolbutamide might be harmful. A different aspect of the public way of regulating is discussed by Ilana Löwy. She examines the difficulties of persuading healthy women to use tamoxifen to prevent breast cancer, including similarities to opposition to hormone replacement therapy, and explains the roots of user-driven regulation. Public regulation receives further scrutiny in Stephen Snelders and Toine Pieters's study of the sleeping pill Halcion, in the different regulatory contexts of the Netherlands, the UK and the US in the 1970s and 1980s. Their research highlights the role of the media in generating public confidence, prompting regulatory action and influencing company policy.
Viviane Quirke addresses a gap in the literature on the British regulatory context by examining the response of Imperial Chemical Industries (ICI) to post-Second World War regulatory measures. She studies the effect of these regulations on the firm in relation to both thalidomide and the beta blocker practolol, arguing that concern for drug safety was present within ICI even before the thalidomide tragedy. Maurice Cassier demonstrates how patents are tools of both administrative and industrial regulation through an analysis of the development of generic drugs for the treatment of AIDS and chronic myelogenous leukaemia in India and Brazil. Cassier also considers the new roles of court cases and appeals procedures in exploiting patent law to facilitate the copying of generic medicines and the availability of treatments. With regard to the juridical way of regulating, Christian Bonah examines the production and marketing of the antibacterial and dermatological drug Stalinon in France in the 1950s and the associated criminal trial. He explores how court trials became no longer merely a way of overseeing the four other ways of regulation, but began to be considered as a distinct fifth juridical way.
Considering the diverse subject material in terms of actors, chronology, discipline, drug type and sector, the comparative and international elements of this book are particularly strong. The editors have succeeded in producing a volume that not only explores the distinct social worlds involved in regulation, but also demonstrates their relevance to today's medical and scientific marketplace in a manner suitable for a wide potential readership.
